ABBVAbbVieRunning, no new patients
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma · Gastroesophageal Junction Adenocarcinoma · Esophageal Adenocarcinoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 185 (final count)
- Started
- Dec 13, 2024
- Main results expected
- Oct 2030
- Fully finished
- Oct 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-Free Survival (PFS) as Assessed by Investigator
Measured over: Through Study Completion, Approximately 6 Years
Percentage of Participants with Objective Response (OR) as Assessed by Investigator
Measured over: Through Study Completion, Approximately 6 Years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06628310 · record last updated 2026-07-21 · checked 2026-11-09 15:47 UTC